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Rhabdomyosarcoma is a common malignancy in children. There are two major types
of rhabdomyosarcomas, the embryonal and the alveolar, differing in cytogenetic and
morphologic features. The alveolar type of rhabdomyosarcoma is frequently associated
with chromosome translocation t(2; 13) and poor clinical prognosis. Pathogenesis of
rhabdomyosarcoma remains obscure, and especially it occurs in the location where skeletal
muscle is absent. We report here that there is a high frequency of association of rhabdomyosarcoma with ataxia telangiectasia mutated (ATM) gene mutation/deletion. Totally
17 cases of rhabdomyosarcoma specimens were studied by immunohistochemical or
immunofluorescent staining with ATM antibody and revealed that 7 of the 17 cases were
negative for ATM expression (41%). Further analyses of rhabdomyosarcoma cell lines
with RT-PCR revealed that in Rh30 cells, an alveolar rhabdomyosarcoma cell line, there
are three separate deletions/mutations of the ATM mRNA. Western blotting analysis of
the Rh30 cellular extract with anti-ATM antibody showed that there is an aberrant form of
ATM protein within the Rh30 cells that are smaller than normal control. These results
suggest, for the first time, a link of ATM gene deletion/mutation with rhabdomyosarcoma,
and since ATM kinase is a crucial regulatory protein in DNA damage repair signaling
pathway, and ATM deletion/mutation may contribute to pathogenesis of rhabdomyosarcoma.
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Rhabdomyosarcoma is a malignant neoplasm of skeletal muscle, and is one of the most
common soft tissue malignancies in the children and adolescent population. Histopathologically rhabdomyosarcoma can be divided into two major subtypes, embryonal
rhabdomyosarcoma representing about 80% of the clinical cases, and alveolar rhabdomyosarcoma representing about 20% of the total cases.1,2 Extensive cytogenetic studies
showed that the embryonal rhabdomyosarcomas are generally associated with loss of
heterozygosity (LOH) for multiple closely linked loci at chromosomal 11p15.5, suggesting
inactivation of one or more tumor-suppressor gene(s) in this region.2,3 But the gene
involved in this region has yet to be identified. Many other associated mutation or amplification of oncogenes, tumor suppressor genes including p53, K-ras, N-ras and N-myc, etc.
are frequently seen, but the roles of these gene mutations/amplifications in pathogenesis
of the tumor remain largely unclear.4,5 The alveolar subtype of rhabdomysarcoma,
however, is consistently associated with two common chromosomal translocations. Most
cases of alveolar rhabdomyosarcoma are associated with a chromosomal translocation t(2;
13) (q35; q14), and less commonly with t(1; 13)(p36; q14).6-9 The t(2; 13) translocation
results in fusion of a portion of the Pax3 gene to a portion of the FKHR gene, leading to
formation of fusion protein Pax3-FKHR. Pax3 gene encodes a transcriptional factor
important in early development program, while FKHR gene encodes another generic
transcriptional factor that is widely expressed in mammalian tissues. The t(1; 13) translocation
results in formation of Pax7-FKHR. Both Pax3-FKHR and Pax7-FKHR were shown to
possess more potent transcriptional activity than its original forms Pax3 and Pax7.10,11
How the chimeric fusion proteins contribute to pathogenesis of rhabdomyosarcoma
remains unclear.
Ataxia telangietasia mutated gene (ATM) is a newly identified member of PI3 kinase
family that is mutated in human autosomal recessive disease, ataxia telangiectasia
(AT).12,13 ATM gene is large, spanning about 150 kbs of genomic DNA, and is located
on chromosome 11q22-23. In response to DNA damage agents such as ionizing irradiation
and chemical agent cisplatin, ATM kinase is activated, leading to a cascade of kinase reactions
regulating cell cycle, apoptosis, and DNA damage repair.14,15 Many downstream target
molecules of ATM kinase were so far identified. These target proteins include the c-Abl
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tyrosine kinase, the p53 tumor suppressor, the Chk1 and Chk2 serine/
threoine kinase, the p34 subunit of replication protein A (RPA),
Chk1 serine/threoine kinase and NBS1 kinase which is mutated in
human autosomal recessive disease Nijmegan breakage syndrome.16-23
Clinical characteristics of AT patients include hypersensitivity to
irradiation, thymic dysplasia, immune defects and higher tendency
to develop malignant tumor, suggesting that ATM function is critical
in DNA damage repair and tumor suppression. However, up to date,
AT patients are not known to develop rhabdomyosarcoma.
In this study, we report an association of human rhabdomyosarcoma with deletion/mutation of ATM gene. This is the first report
so far of ATM gene associated with solid malignancy except for the
mantle cell lymphoma, a malignant tumor in lymphoid origin. The
association of ATM gene mutation/deletion with rhabdomyosarcoma
suggests a link of ATM gene with cancer risk, and ATM kinase may
contribute to pathogenesis of rhabdomyosarcoma.

MATERIALS AND METHODS

Table 1

OLIGONUCLEOTIDE PRIMERS

FOR

RT-PCR AMPLIFICATIONS

Primer

Oligonucleotide Sequence (5’–3’)

1A (exon 36)

CTT CAG TFF ACC TTC ATA ATG C

1B (exon 43)

CCA TAC AAA CTA TCT GGC TCC

2A (exon 29)

CAG AGA TTG TGG TGG AGT TAT TG

2B (exon 36)

GCA TTA TGA AGG TCC ACT GAA G

3A (exon 42/43)

CTG GAA TAA GTT TAC AGG ATC TTC

3B (exon 51)

GAT GAT TTC ATG TAG TTT TCA ATT C

4A (exon 56)

AAG ATG TTG TTG TCC CTA CTA TG

4B (exon 65)

AAG GCT GAA TGAAAG GGT AAT TC

5A (exon 51)

GAT GGA GAA TGA AAG GGT AAT TC

5B (exon 57)

AGT CAC CAG ATT TCC ATA TTC TC

6A (exon 22)

CTA GGT CAA AGC AAT ATG GAC TC

CAT GCG ATG GAA AAT GAG GTG
Immunohistochemical and Immunofluorescent Staining. Human 6B (exon 30)
rhabdomyosarcoma tumor specimens were obtained from the Department 7A (exon 13)
TGC CTC CAA TTC TTC ACA G
of Pathology, the Children’s Hospital San Diego. All human tissues were
CCT CTC CTT TGT TAG ATG CC
formalin fixed, paraffin embedded and were previously used for diagnostic 7B (exon 22/23)
purposes. Current study was approved by the Institutional Review Board at
University of California, San Diego (IRB). The specimens were sectioned at
RESULTS
5 micron in thickness, and used for immunohistochemical staining with
Totally 17 patients specimen were retrieved from the archived tissue
ATM antibody as described.18 Briefly, the sections were de-paraffinized in
blocks. The clinical characteristics of these patients were listed as in Table 1.
xylene solution, dehydrated and rehydrated in 100%, 90% and 70% alcohol.
Some patient’s clinical information was not available at the time of the
The specimens were immersed in Antigen Retrieval solution (commercially
study. These patients all carried clinical histopathological diagnoses of rhabavailable from Dako Corp. CA) at 90˚C for 30 minutes to unmask the antigen
domyosarcoma (embryonal or alveolar type), and showed immunostaining
followed by incubation with primary antibody against ATM protein at 40˚C
positivity for myogenin, a specific skeletal muscle marker. Immunofluoresovernight. The primary anti-ATM antibody was kindly provided by Dr.
cent or immunohistochemical staining with anti-ATM antibody was
Gately and as described previously.18 The second antibody was either
performed on the total of 17 specimens, and 7 of the 17 rhabdomyosarcomas
immunoperoxidase conjugated for immunochemical stains or Cy3 conjuwere negative for ATM protein (41%) (see Table 1). Totally 10 of the 17
gated anti-rabbit IgG for immunofluorescent stains (Molecular Probes,
were positive for ATM kinase (59%). ATM protein was predominantly
OR). For immunofluorescent staining for the tumor cell lines, the tumor
cells were cultured on the glass coverslips, fixed by 4%
paraformaldehyde and stained with primary antibody Table 2 RMS PATIENTS AND IMMUNOSTAINING PROFILES
against ATM and MyoD as described.24
Patients
Tumo location
Subtype
Signal intensity and location
Cell Culture, RNA Isolation, Reverse Transcription Case No.
and PCR. Rhabdomyosarcoma cell lines, such as Rh3, 1
15/M
paratesticular
embryonal
ATM (–)
Rh4, Rh 28, RH30 and RD cells were obtained from Dr.
19/M
prostate/bone marrow alveolar
ATM (+)/weakly/cytoplasmic
Karen Arden, Ludwig Institute of Cancer Research at 2
UCSD. The tumor cell lines were cultured and maintained 3
4/M
salivary gland
embryonal
ATM (+)/cytoplasmic
as described.24 The total RNA was isolated from the
3/M
pelvis
embryonal
ATM (+)/cytoplasmic
cultured cells using Trizol RNA isolation kit (GBCOL- 4
BRL, Besthesda, MD). The cDNA synthesis was 5
4/M
paraspinal
alveolar
ATM (+)/weakly/cytoplasmic
performed using the cDNA synthesis kit (Supersccript,
4/M
skull base
embryonal
ATM (+)/cytoplasmic
GBCOL-BRL) using random hexamer and oligo-d(T) 6
primers following the instruction from the manufacturer. 7
6/M
abdomen
alveolar
ATM (–)
The total cDNA was directly used as templates for PCR
unknown
unknown
alveolar
ATM (+)/cytoplasmic
amplification for ATM gene using the primer pairs in 8
Table 1 The PCR products were electrophoresed in 1% 9
unknown
unknown
embryonal
ATM (+)/cytoplasmic
agarose gel and visualised using ethidium bromide.
10
unknown
unknown
embryonal
ATM (+)/cytoplasmic
Western Blotting of ATM Protein. The rhabdomyosarcoma cells are cultured and maintained as 11
unknown
unknown
embryonal
ATM (–)
described.24 The cellular proteins were prepared, separated
12
unknown
unknown
unknown
ATM (–)
on 4% polyacrylamide gel and transferred onto nitrocellulose membrane. The immobilized proteins were 13
unknown
unknown
unknown
ATM (–)
incubated with anti-ATM antibody.18 The proteins of
14
unknown
unknown
unknown
ATM (–)
interest were detected by enhanced immunochemilumi24
15
unknown
unknown
unknown
ATM (–)
nescence kit from Amersham Life Sciences.
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Figure 1. Immunostaining of rhabdomyosarcoma cases. (A) Immunofluorescent staining of five representative cases with anti-ATM antibody. PT: patient. The
secondary antibody was conjugated to rhodamine. The positive signals were red fluorescent. The photograph was taken at 200X using Zeiss UV fluorescent microscope. (B) Immunoperoxidase staining of the rhabdomyosarcoma tumor with negative control. The positive staining was seen in cytoplasm. (C)
Immunofluorescent staining of the cultured RD cells with antibodies against ATM and MyoD. The signals were seen in the nuclei. The photograph was taken
at 400X.

located in cytoplasm in the tumor sections and interestingly, predominantly
seen in the nuclei in the rhabdomyosarcoma cell line, as those seen with
myoD staining (RD cells) (Fig. 1A and Fig. 1B vs. Fig. 1C). There is no
difference in staining pattern in regard to the subtypes of the rhabdomyosarcomas, namely embryonal or alveolar subtypes.
It is surprising to note that 7 of the 17 (41%) rhabdomyosarcoma
specimens stained negatively for the presence of ATM protein. Under the
normal condition, ATM expression is ubiquitous. To further confirm the
immunostaining results, two different approaches were taken. One was to
see if the ATM mRNA is properly transcribed, and another is to directly see
the ATM protein itself by Western blotting analysis from the tumors and

89

compare with the normal form. Due to the limited resource of the fresh
tumor samples, we turned to the cell culture system and used the well-established rhabdomyosarcoma cell lines. First, we designed eight pairs of
oligonucleotide primers encompassing the almost entire coding sequence of
ATM mRNA based on the published cDNA sequence (Genbank accession
number U33841)25 (see Table 2). The primer designing strategy is shown
in Figure 2A. ATM mRNA is approximately 9.4 kbs in length and contains
multiple protein binding domains for its kinase activity and interaction with
other cellular proteins (Fig. 2A). We used reverse transcription-PCR method
to analyze three different rhabdomyosarcoma cell lines, RD cells (embryonal),
Rh28, Rh30 (alveolar), and mouse normal myoblast C2C12 cells. The
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Figure 2. (A) Diagrammatic representation of ATM structure and RT-PCR strategy. The primer pairs were designed as shown. (B) RT-PCR amplification of ATM
mRNA in the different cells.

human foreskin fibroblasts were used as the control cells. The mRNA was
isolated from these cells and used for RT-PCR assays. As shown in Figure
2B, in normal fibroblasts, RD cells, Rh28 cells, the amplified DNA fragments
were identical in regard to the lengths in comparing with the control
fibroblasts, whereas in Rh30 cells, two fragments in #1 and #7 lanes (0.94
kbs in Lane #1, and 1.3 kbs in Lane #7) were absent, and in Lane #6, the
fragment amplified was approximately 200 bps smaller than that seen in the
fibroblasts and other rhabdomyosarcoma cells (Fig. 2B). The combined
length of missing DNA sequence is estimated 2.4 kb (fragment #1, plus
fragment #7, and additional 200 bps in Lane #6).
The next question is whether ATM protein is normally translated from
ATM mRNA and expressed in the rhabdomyosarcoma cells. We analyzed
the ATM protein in different cell lines. In human Hela cells and human
normal foreskin fibroblasts, the ATM was estimated to be 360 kD, consistent
with the results previously described.12,13 In three rhabdomyosarcoma cell
lines (RD, Rh28 and RH30), there was one aberrant form of ATM protein
(~260 kD) that was significantly smaller than that seen in the normal
fibroblasts and the Hela cells (Fig. 3). The levels of ATM expression in these
three rhabdomyosarcoma cell lines are not identical, and Rh30 cells seemed
to express less ATM than the other two Rhabdomyosarcoma cells. The
murine ATM proteins from C2C12 and 10T 1/2 cells were significantly
different in size and there appeared to be two species of ATM proteins in
murine cells.

DISCUSSION
ATM gene is a member of PI3 kinase family. ATM kinase is critical
in DNA damage signaling pathway. In response to DNA damage
induced by ionizing radiation or chemical agents such as cisplatin,
ATM kinase is activated and phosphorylates a number of downstream
regulatory proteins important for cell cycle arrest, growth control,
www.landesbioscience.com

Figure 3. Western blotting of ATM protein in the cultured cells. The whole
cell lysates were separated on 4.5% SDS-PAGE and the ATM protein was
detected by using anti-ATM antibody. Lane 1: Hela cells; Lane 2: RD cells;
Lane 3; Rh28 cells; Lane 4: Rh30 cells; Lane 5: normal human foreskin
fibroblast cells; Lane 6: C2C12 mouse myoblasts; Lane 7: mouse 10T 1/2
fibroblasts.
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apoptosis and DNA repair.26-29 AT patients are known to be predisposed to a variety of cancers, and the fibroblasts of AT patients are
hypersensitive to ionizing radiation.30 Although many reports
showed the association of ATM mutation with risk of a number of
different human malignancies, including prostate cancer, breast
cancer, ovarian cancer, B-cell chronic lymphocytic leukemia and
mantle cell lymphoma, the underlying molecular mechanism by
which ATM gene causes these changes are not well understood.31-36
There is so far no study showing the association of ATM gene
mutation with any solid tumor. There is enormous epidemiological
interest in establishing the link of ATM gene abnormality with
cancer risk, since ATM heterozygotes are estimated to represent
1.5% of total population.
We studied the immunostaining characteristics of ATM protein
in clinical rhabdomyosarcoma cases and found that a significantly
high number of cases lacked the proper ATM gene product (41% in
17 cases). The clinical significance of this finding is unclear at this
point. There is high percentage of clinical rhabdomyosarcoma cases
associated with p53 gene mutation/deletion. The p53 mutant mice
tend to develop rhabdomyosarcoma.30 P53 is a tumor suppressor
regulating cell cycle control and apoptosis, and p53 is one of the
many downstream targets of ATM kinase.26,28 ATM phosphorylate
p53 at Serine 15 in response to DNA damage agents.17 It is
unknown how the mutated ATM contributes to pathogenesis of
rhabdomyosarcoma in the presence of the mutated p53. In fact, the
rhabdomyosarcoma cells Rh30 is known to have p53 mutation, and
is also positive for t(2; 13) chromosomal translocation.11 Further
investigations are needed to address these important questions.
The finding of ATM protein predominantly present in the
cytoplasm, but not the nucleus of the tumor sections suggests a
different role of ATM in the tumor cells. In the tumor cell lines, the
ATM protein is present predominantly in the nucleus. The underlying
significance of this finding is unclear. Presumably ATM protein in
the cytoplasm may function differently in the tumor cells in vivo
from that in the nucleus seen in the cell culture.
The murine ATM was found significantly different in size,
although the ATM knockout mice recapitulate the phenotypic
features of A-T patients.37 This species difference may be important
in interpreting the data from human cells and from murine cells.
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